Rinvoq is the brand name for upadacitinib, a prescription medication used to treat several inflammatory and autoimmune conditions. It comes as an extended-release tablet taken once daily for most approved uses, which sounds pleasantly simple. Unfortunately, the immune system rarely reads the “keep it simple” memo.
Rinvoq can reduce inflammation, relieve symptoms, and help some people regain daily function when other treatments have not worked well enough. It also carries important safety warnings involving infections, blood clots, cardiovascular events, cancer, and other potentially serious complications. That combination of meaningful benefits and meaningful risks makes careful patient selection, laboratory monitoring, and regular medical follow-up essential.
This guide explains what Rinvoq treats, how it works, typical dosages, common and serious side effects, drug interactions, current costs, and what the treatment experience may look like in everyday life.
What Is Rinvoq?
Rinvoq contains upadacitinib, a type of medicine known as a Janus kinase inhibitor, or JAK inhibitor. Janus kinases are enzymes that help transmit signals involved in inflammation and immune activity. By interfering with selected JAK signaling pathways, Rinvoq can calm an overactive immune response.
Imagine inflammatory signals as a group chat that never stops buzzing. Rinvoq does not throw the immune system’s phone into a lake, but it can mute some of the loudest notifications.
Rinvoq is considered a targeted synthetic disease-modifying medication. Unlike biologic drugs, which are usually injected or infused, Rinvoq is a small-molecule treatment taken by mouth. It controls disease activity rather than permanently curing the underlying condition.
Available forms and strengths
Rinvoq extended-release tablets are available in 15 mg, 30 mg, and 45 mg strengths. The tablets must be swallowed whole and should not be split, crushed, or chewed because doing so may interfere with the extended-release design.
Rinvoq LQ is a 1 mg/mL oral solution used for certain pediatric patients. It is not directly interchangeable with the extended-release tablets. Any change between the liquid and tablet formulations must be directed by a healthcare professional.
What Is Rinvoq Used For?
In the United States, Rinvoq or Rinvoq LQ is FDA-approved for nine inflammatory conditions. Eligibility differs by disease, age, previous treatment, and medical history.
Rheumatoid arthritis
Rinvoq treats adults with moderately to severely active rheumatoid arthritis who did not respond adequately to, or could not tolerate, one or more tumor necrosis factor inhibitors, commonly called TNF blockers.
Psoriatic arthritis
It may be prescribed for active psoriatic arthritis in adults and children age 2 or older after an inadequate response or intolerance to at least one TNF blocker. Pediatric dosing is determined by body weight.
Atopic dermatitis
Rinvoq is approved for adults and adolescents age 12 or older with refractory, moderate-to-severe atopic dermatitis, also called eczema. It is generally considered when other systemic treatments, including biologics, have not controlled the disease or are not advisable.
Ulcerative colitis
Adults with moderately to severely active ulcerative colitis may receive Rinvoq after an inadequate response or intolerance to a TNF blocker. When TNF blockers are clinically inadvisable, Rinvoq may be considered after at least one other approved systemic treatment.
Crohn’s disease
Rinvoq is also used for moderately to severely active Crohn’s disease in adults under treatment circumstances similar to those for ulcerative colitis.
Axial spondyloarthritis conditions
Approved uses include active ankylosing spondylitis and active non-radiographic axial spondyloarthritis with objective evidence of inflammation in adults who did not respond adequately to, or could not tolerate, TNF-blocker therapy.
Polyarticular juvenile idiopathic arthritis
Rinvoq or Rinvoq LQ can treat active polyarticular juvenile idiopathic arthritis in children age 2 or older following an inadequate response or intolerance to one or more TNF blockers.
Giant cell arteritis
Rinvoq is approved for adults with giant cell arteritis, an inflammatory disease affecting medium and large arteries. Treatment begins with Rinvoq alongside a tapering course of corticosteroids. Rinvoq may later be continued alone after corticosteroids are discontinued.
Rinvoq is generally not recommended in combination with another JAK inhibitor, a biologic disease-modifying drug, or powerful immunosuppressants such as azathioprine or cyclosporine. Combining therapies that heavily suppress immune function can increase risk without necessarily adding useful benefit.
Rinvoq Dosage
The appropriate Rinvoq dosage depends on the condition being treated, age, body weight, kidney and liver function, interacting medications, and individual risk factors. The following dosages summarize standard U.S. prescribing recommendations and are not personalized instructions.
Standard adult dosing
- Rheumatoid arthritis: 15 mg once daily.
- Adult psoriatic arthritis: 15 mg once daily.
- Ankylosing spondylitis: 15 mg once daily.
- Non-radiographic axial spondyloarthritis: 15 mg once daily.
- Giant cell arteritis: 15 mg once daily with a tapering corticosteroid course, followed by possible Rinvoq monotherapy.
Atopic dermatitis dosing
Adults younger than 65 and adolescents age 12 or older who weigh at least 40 kilograms, or about 88 pounds, generally begin with 15 mg once daily. A doctor may increase the dose to 30 mg once daily if the response is inadequate and the expected benefit outweighs the added risk.
For adults age 65 or older, the recommended dose is 15 mg once daily. The lowest effective dose should be used to maintain disease control.
Ulcerative colitis dosing
The usual induction dose is 45 mg once daily for eight weeks. After induction, the usual maintenance dose is 15 mg once daily. A 30 mg maintenance dose may be considered for severe, extensive, or treatment-resistant disease.
Crohn’s disease dosing
The usual induction dose is 45 mg once daily for 12 weeks. Maintenance treatment is generally 15 mg once daily, although 30 mg once daily may be considered for refractory, severe, or extensive disease.
Pediatric dosing
For psoriatic arthritis and polyarticular juvenile idiopathic arthritis, dosing is based on body weight. Children weighing less than 30 kilograms generally receive Rinvoq LQ oral solution twice daily. Those weighing at least 30 kilograms may receive either a weight-based liquid dose or one 15 mg extended-release tablet daily, as directed by the prescriber.
How to take Rinvoq
- Take it at approximately the same time each day.
- It may be taken with or without food.
- Swallow extended-release tablets whole.
- Avoid grapefruit and grapefruit juice, which can increase upadacitinib exposure.
- Do not double a dose to compensate for a missed tablet unless specifically instructed by a healthcare professional.
- Do not change, stop, or restart treatment without contacting the prescriber.
Common Rinvoq Side Effects
Side effects vary partly according to the condition and dosage. A person taking 45 mg during inflammatory bowel disease induction may have a different experience from someone taking 15 mg for arthritis.
Frequently reported Rinvoq side effects include:
- Upper respiratory infections, including colds and sinus infections
- Acne
- Headache
- Nausea or abdominal discomfort
- Cough
- Fever
- Fatigue
- Cold sores or other herpes simplex infections
- Shingles
- Folliculitis
- Rash
- Increased cholesterol
- Elevated liver enzymes
- Increased creatine phosphokinase, a muscle-related laboratory marker
- Low white or red blood cell counts
Acne is especially common in people using Rinvoq for atopic dermatitis. It may be mild and manageable, but severe, painful, or persistent acne should be discussed with a dermatologist rather than attacked with every skin-care product in the bathroom cabinet.
Serious Side Effects and Boxed Warnings
Rinvoq carries the FDA’s strongest safety warning. The boxed warning covers serious infections, increased mortality, malignancy, major cardiovascular events, and thrombosis.
Some class-warning evidence came from a large safety study of another JAK inhibitor in older rheumatoid arthritis patients with cardiovascular risk factors. The FDA applies these concerns to Rinvoq and other medications in the class because they have related mechanisms and may share similar risks.
Serious infections
Rinvoq reduces immune-system activity and may make it harder to fight infections. Tuberculosis, pneumonia, shingles, invasive fungal infections, hepatitis B reactivation, and other opportunistic infections have occurred. Treatment may need to be paused until a serious infection is controlled.
Blood clots
Deep vein thrombosis, pulmonary embolism, and arterial thrombosis have been reported with JAK inhibitors. Seek urgent care for sudden shortness of breath, chest pain, coughing up blood, or swelling, warmth, redness, or pain in one leg or arm.
Heart attack and stroke
The risk may be particularly important for people age 50 or older who have cardiovascular risk factors, including smoking, diabetes, high blood pressure, high cholesterol, or a previous cardiovascular event. Emergency symptoms include chest pressure, sudden weakness, facial drooping, speech difficulty, severe dizziness, or an unexplained sudden headache.
Cancer
Lymphoma, lung cancer, and other malignancies have been observed in patients taking JAK inhibitors. Current and former smokers may face additional risk. Periodic skin examinations may be recommended, especially for people with risk factors for non-melanoma skin cancer.
Gastrointestinal perforation
A tear in the stomach or intestinal wall is uncommon but potentially life-threatening. Risk may be higher in people with diverticulitis or those using nonsteroidal anti-inflammatory drugs or corticosteroids. New severe abdominal pain accompanied by fever, chills, nausea, or vomiting requires prompt evaluation.
Severe allergic reactions
Stop taking the medication and obtain emergency help for facial or throat swelling, trouble breathing, widespread hives, or other signs of anaphylaxis or angioedema.
Sudden vision changes
Retinal detachment was reported in clinical trials involving people with atopic dermatitis. Contact a healthcare professional immediately for sudden flashes of light, new floaters, a curtain-like shadow, or abrupt loss of vision.
Tests and Monitoring Before and During Treatment
Before prescribing Rinvoq, a clinician may review or order:
- Testing for active or latent tuberculosis
- Hepatitis B and hepatitis C screening
- A complete blood count
- Liver-function tests
- Kidney-function assessment when relevant
- Pregnancy testing for patients who could become pregnant
- A vaccination review
- Cardiovascular, clotting, infection, smoking, and cancer history
Treatment is generally not started when the absolute lymphocyte count is below 500 cells per cubic millimeter, the absolute neutrophil count is below 1,000 cells per cubic millimeter, or hemoglobin is below 8 g/dL.
Cholesterol should usually be checked approximately 12 weeks after treatment begins and periodically afterward. Blood counts and liver enzymes may also be repeated according to the patient’s condition and treatment plan.
Rinvoq Interactions and Precautions
Medication interactions
Strong CYP3A4 inhibitors can increase upadacitinib levels. Examples include clarithromycin and ketoconazole. Some patients taking these drugs require a lower Rinvoq dose, particularly when being treated for atopic dermatitis, ulcerative colitis, or Crohn’s disease.
Strong CYP3A4 inducers such as rifampin can lower Rinvoq exposure and reduce its effectiveness. These combinations are generally not recommended.
Patients should give their prescriber and pharmacist a complete list of prescription drugs, over-the-counter medicines, vitamins, and herbal products. “It is natural” is not a magical interaction-proof force field.
Vaccines
Live vaccines should be avoided during treatment and immediately before Rinvoq is started. Patients should ideally be brought up to date on recommended vaccinations beforehand, including appropriate shingles vaccination. Non-live vaccines may generally be used, although immune-suppressing treatment can sometimes reduce the response.
Pregnancy and breastfeeding
Based on animal studies, Rinvoq may harm a developing fetus. Patients who can become pregnant should use effective contraception during treatment and for four weeks after the final dose.
Breastfeeding is not recommended while taking Rinvoq or for six days after the last dose because of the potential for serious reactions in a nursing infant.
How Much Does Rinvoq Cost?
Rinvoq is a high-cost specialty medication. As of January 6, 2026, the manufacturer listed a wholesale acquisition cost of $7,090.41 for a 30-day supply. Pharmacy cash prices may differ, and commonly quoted prices for 30 tablets are often above $6,000 without insurance or assistance.
The list price is not necessarily the amount a patient pays. Actual out-of-pocket costs depend on the insurance plan, deductible, formulary tier, prior-authorization rules, specialty-pharmacy requirements, and whether financial assistance is available.
Rinvoq remains a brand-name medication without a lower-cost generic equivalent in the United States. Eligible patients with commercial insurance may qualify for a manufacturer savings card that can reduce the monthly copay substantially, sometimes to as little as $0. Eligibility rules, annual limits, and terms apply, and federal insurance beneficiaries such as people enrolled in Medicare or Medicaid are generally excluded from commercial copay-card programs.
Patients with government insurance or no insurance can ask the manufacturer, specialty pharmacy, hospital financial counselor, or prescribing clinic about patient-assistance programs. Before the first dose, it is wise to confirm both the initial authorization and the refill process. Nobody enjoys discovering on day 29 that a form has wandered into administrative purgatory.
What the Rinvoq Treatment Experience May Be Like
The following is a practical composite of issues commonly encountered during treatment, not an individual patient testimonial.
The Rinvoq experience often begins before the first pill is swallowed. A specialist may discuss why a previous medication did not work, review cardiovascular and infection risks, order blood tests, and check for tuberculosis and hepatitis. Patients may also be encouraged to complete vaccinations before treatment. This preparation can feel like an obstacle course, but it is designed to uncover risks that would be much less entertaining if discovered after therapy begins.
Insurance approval is frequently the next challenge. Because Rinvoq is expensive, insurers may request documentation showing that the diagnosis meets coverage criteria and that another treatment was ineffective, poorly tolerated, or medically inadvisable. The doctor’s office, insurer, specialty pharmacy, and manufacturer support program may all become involved. Keeping a list of phone numbers, dates, authorization numbers, and refill deadlines can prevent repeated conversations that begin with, “I spoke to someone about this last Tuesday.”
Once treatment starts, the tablet’s once-daily schedule is convenient for many adults. Linking it to a consistent routine, such as breakfast or brushing teeth, can help prevent missed doses. Medication reminders and a simple symptom diary are useful. Depending on the disease, patients might track morning stiffness, swollen joints, skin itch, bowel frequency, abdominal pain, fatigue, sleep, or the need for rescue medication.
Benefits do not appear on an identical timetable for everyone. Some patients may notice changes in itching, joint discomfort, or bowel symptoms within the first few weeks, while others require more time. Feeling slightly better does not necessarily mean inflammation is fully controlled, and a slow response does not automatically mean treatment has failed. The prescribing specialist typically considers symptoms, physical findings, laboratory results, and sometimes imaging or endoscopy before deciding whether the medication is working adequately.
Mild side effects can also emerge early. Acne, headache, nausea, fatigue, cold sores, or a respiratory infection may occur. A diary can help determine whether symptoms are temporary, recurring, or connected with dose changes. Patients should not quietly endure a troublesome reaction because they assume it is “the price of treatment.” Many side effects can be evaluated or managed without immediately abandoning an otherwise effective therapy.
Follow-up blood work is an important part of the experience. Cholesterol may rise even when a person feels perfectly well, which is why laboratory monitoring matters. Blood-cell counts and liver enzymes may also change without producing obvious symptoms. A clinician may repeat tests, treat an abnormal cholesterol level, pause therapy, adjust another medication, or reconsider Rinvoq depending on the result.
Patients gradually learn which symptoms can wait for a routine appointment and which require immediate attention. A mild headache is different from sudden weakness and slurred speech. Ordinary muscle soreness is different from one-sided leg swelling and chest pain. A common cold is different from persistent fever, shortness of breath, or an infection that rapidly worsens. Written emergency guidance from the treatment team can make those decisions less stressful.
Long-term success involves more than asking whether Rinvoq “works.” The broader question is whether it provides enough symptom relief and disease control to justify its risks, monitoring burden, and cost. For some people, the answer may be clearly yes. For others, recurring infections, laboratory abnormalities, inadequate improvement, insurance problems, or personal risk factors may make another treatment more suitable. Shared decision-making remains essential because the best medication is not simply the strongest optionit is the option whose benefits and risks make sense for the individual taking it.
Final Thoughts
Rinvoq is a versatile oral JAK inhibitor used across rheumatology, dermatology, gastroenterology, and vascular medicine. Its once-daily tablet can be more convenient than an injection or infusion, and it may provide meaningful relief for people whose inflammatory disease has remained active despite other treatments.
Convenience, however, should not be confused with casual treatment. Rinvoq can affect infection risk, blood counts, cholesterol, liver enzymes, cardiovascular health, clotting risk, and pregnancy. Appropriate screening and regular follow-up are central parts of using it safely.
Anyone considering Rinvoq should discuss previous treatments, smoking history, heart and clotting risks, infections, cancer history, pregnancy plans, vaccinations, current medications, expected costs, and monitoring requirements with the prescribing specialist.
